Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
Status:
Completed
Trial end date:
2021-05-21
Target enrollment:
Participant gender:
Summary
This protocol will serve as a platform for assessing treatments for adult patients
hospitalized for medical management of COVID-19 without related serious end-organ failure.
Trials will involve sites around the world strategically chosen to ensure rapid enrollment.
This trial will compare hyperimmune intravenous immunoglobulin (hIVIG) with matched placebo,
when added to standard of care (SOC), for preventing further disease progression and
mortality related to COVID-19. SOC will include remdesivir unless it is contraindicated for
an individual patient.
Phase:
Phase 3
Details
Lead Sponsor:
University of Minnesota
Collaborators:
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) The International Network for Strategic Initiatives in Global HIV Trials